2% of patients, 1/62, required permanent discontinuation of treatment due to an adverse reaction of altered mood.1
2% of patients, 1/62, required a dose reduction due to decreased appetite.1
34% of patients required dose interruptions due to adverse reactions.
The most frequent adverse reactions requiring dose interruptions in ≥3% of patients were hemorrhage, increased ALT, and increased AST.1
Serious adverse reactions occurred in 37% of patients who received TAZVERIK®. Serious adverse reactions in ≥3% of patients who received TAZVERIK were hemorrhage, pleural effusion, skin infection, dyspnea, pain, and respiratory distress.1
The most common adverse reactions (≥20%) were pain (52%), fatigue (47%), nausea (36%), decreased appetite (26%), vomiting (24%), and constipation (21%).1
ALT=alanine aminotransferase; AST=aspartate aminotransferase.
Select Laboratory Abnormalities (≥10%) Worsening From Baseline in Patients With Epithelioid Sarcoma Treated With TAZVERIK1
|ALL GRADES (%)||GRADE 3 OR 4 (%)|
|Decreased white blood cell count||19||0|
|Increased alkaline phosphatase||23||1.7|
|Increased aspartate aminotransferase||18||3.5|
|Increased partial thromboplastin time||15||5|
|Increased alanine aminotransferase||14||3.4|
*The denominator used to calculate the rate varied from 39 to 61 based on the number of patients with a baseline value and at least one post-treatment value.
TAZVERIK does not require special monitoring for laboratory abnormalities.
Reference: 1. TAZVERIK (tazemetostat) Prescribing Information. Cambridge, MA: Epizyme, Inc., July 2020.